ReviewExpert review of vaccines2013
Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse.
Review in Expert review of vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Vaccines against Drug Abuse-Are We There Yet?Vaccines · 2022Review
- Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.Vaccine · 2019Article
- Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.Bioorganic & medicinal chemistry · 2019Article
- Novel technologies in detection, treatment and prevention of substance use disorders.Journal of food and drug analysis · 2019Review
- Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.Scientific reports · 2018Article
- Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.Journal of bioethical inquiry · 2018Article
- Biologics to treat substance use disorders: Current status and new directions.Human vaccines & immunotherapeutics · 2016Review
- New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?CNS drugs · 2016Review
- Biologic Approaches to Treat Substance-Use Disorders.Trends in pharmacological sciences · 2015Review
- Flagellin as carrier and adjuvant in cocaine vaccine development.Molecular pharmaceutics · 2015Article
- Current approaches for the discovery of drugs that deter substance and drug abuse.Expert opinion on drug discovery · 2014Review
- The future potential for cocaine vaccines.Expert opinion on biological therapy · 2014Review
- Article
- Vaccines against drugs of abuse: where are we now?Therapeutic advances in vaccines · 2014Review
- Article
- New directions in nicotine vaccine design and use.Advances in pharmacology (San Diego, Calif.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
This review addresses potential new treatments for stimulant drugs of abuse, especially cocaine. Clinical trials of vaccines against cocaine and nicotine have been completed with the generally encouraging result that subjects showing high titers of antidrug antibody experience a reduction in drug reward, which may aid in cessation. New vaccine technologies, including gene transfer of highly optimized monoclonal antibodies, are likely to improve such outcomes further. In the special case of cocaine abuse, a metabolic enzyme is emerging as an alternative or added therapeutic intervention, which would also involve gene transfer. Such approaches still require extensive studies of safety and efficacy, but they may eventually contribute to a robust form of in vivo drug interception that greatly reduces the risks of addiction relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.